NCI-Designated Cancer Center

Director’s Statement
Ze'ev Ronai, Ph.D., sitting outside on Institute campus

"Our cancer researchers leverage the expertise of the institute’s outstanding Core facilities to develop novel diagnostic and therapeutic modalities."

Forty investigators at the our Cancer Center collaborate to address unmet clinical needs by conducting translational studies of tumor cell development, metastasis and resistance to therapy. In doing so, they partner with our dedicated Core Facilities which provide state-of-the art technical expertise needed to conduct today’s cutting-edge cancer research. These efforts require input from specialists in many fields, including immunologists, neurobiologists, cancer biologists, and experts in metabolism, the microbiome, and aging. As one of seven official basic cancer centers designated by the National Cancer Institute (NCI)—the highest federal rating a cancer center can achieve—we advance the field in part by leveraging the unprecedented capabilities of our Prebys Center for Chemical Genomics, which offers second-to-none technical expertise in drug discovery. The Prebys Center conducts phenotypic high-throughput screens for small molecules that will serve as the basis for tomorrow’s therapies. The fact that therapeutic strategies developed here have already successfully undergone clinical evaluation strengthens our resolve to seek solutions for patients with cancer and decrease the burden of this disease worldwide.

Ze'ev Ronai, Ph.D.
ad interim Center Director